FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.
What happened
FDA reviewed Beaute Bounty’s website in September 2026 and found it sells Evgenis Totipotent Embryonic Stem Cells, Laennec, and Melsmon Placenta Japan for allogeneic use. The website claims these embryonic stem cell and placenta-derived products treat conditions including Parkinson’s disease, diabetes, cardiovascular disease, anemia, and spinal cord injury. FDA said the products are unapproved new drugs and unlicensed biological products and do not meet the homologous-use criterion for human cell and tissue products (HCT/Ps).
What FDA found
FDA says the products are unapproved new drugs because no approved drug application is in effect.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)FDA says the products are unlicensed biological products because no biologics license application (BLA) is approved.
section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1)FDA says website claims that the products treat diseases or affect body function make them drugs.
section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1)FDA says the products are intended for non-homologous uses such as treating neurodegenerative disease, cardiovascular disease, diabetes, anemia, and revascularization.
21 CFR 1271.10(a)(2); 21 CFR 1271.3(c)FDA says the products fail to meet all criteria in 21 CFR 1271.10(a) and no exception in 21 CFR 1271.15 applies.
21 CFR 1271.10(a); 21 CFR 1271.15FDA says introducing or delivering the products into interstate commerce is prohibited.
section 301(d) of the FD&C Act, 21 U.S.C. § 331(d)
What FDA wants
FDA asks Beaute Bounty to respond in writing within 15 working days with specific steps taken or planned to address the violations and prevent recurrence, plus documentation. If the company disagrees or needs more time, it must explain why and give a completion timeframe.
Who should pay attention
- clinics and consumers buying stem cell or placenta products online
- distributors and retailers of imported biological products
- companies marketing human cell and tissue products with disease claims
This is a summary. Read the original letter on fda.gov.